PE20090552A1 - Compuestos de pirimidina hidrazida como inhibidores de pgds - Google Patents

Compuestos de pirimidina hidrazida como inhibidores de pgds

Info

Publication number
PE20090552A1
PE20090552A1 PE2008000555A PE2008000555A PE20090552A1 PE 20090552 A1 PE20090552 A1 PE 20090552A1 PE 2008000555 A PE2008000555 A PE 2008000555A PE 2008000555 A PE2008000555 A PE 2008000555A PE 20090552 A1 PE20090552 A1 PE 20090552A1
Authority
PE
Peru
Prior art keywords
alergic
methyl
pyrimidine
fluoro
terminary
Prior art date
Application number
PE2008000555A
Other languages
English (en)
Inventor
Suzanne C Aldous
Michael W Fennie
John Z Jiang
Stanly John
Lan Mu
Brian Pegrift
Barbara Rauckman
Jeffrey S Sabol
Grzegorz T Stoklosa
Sukanthini Thurairatnam
Christopher L Vandeusen
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20090552A1 publication Critical patent/PE20090552A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRIMIDINA HIDRAZINA DE FORMULA (I), DONDE R1 ES ALQUILO C1-C6, CICLOALQUILO C3-C6, HALOALQUILO C1-C4, ENTRE OTROS; R2 ES H O ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO CON HALOGENO; R3 ES H, ALQUILO, ARILO O HETEROARILO; R4 ES H, CICLOALQUILO C3-C10, ARILO C6-C14, ENTRE OTROS; L1 ES UN ENLACE, -O-, -C(=O)-, ALQUILENO C1-C2, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (5-FLUORO-2-METIL-INDOL-1-IL)-AMIDA DEL ACIDO 2-PIRIDIN-3-IL-PIRIMIDINA-5-CARBOXILICO, (5-FLUORO-2-METIL-INDOL-1-IL)AMIDA DEL ACIDO 2-(3-FLUORO-FENIL)-4-METIL-PIRIMIDINA-5-CARBOXILICO, (5-FLUORO-3-METIL-INDOL-1-IL)AMIDA DEL ACIDO 4-METIL-2-PIRIDIN-2-IL-PIRIMIDINA-5-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA PROSTAGLANDINA D SINTASA (PGDS), PARTICULARMENTE, TIENEN ACTIVIDAD INHIBITORIA SOBRE LAS PROSTANGLANDINAS D2 SINTASA (PGD2) Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS ALERGICOS Y/O INFLAMATORIOS TALES COMO RINITIS ALERGICA, ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ENTRE OTRAS
PE2008000555A 2007-03-30 2008-03-27 Compuestos de pirimidina hidrazida como inhibidores de pgds PE20090552A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90917107P 2007-03-30 2007-03-30

Publications (1)

Publication Number Publication Date
PE20090552A1 true PE20090552A1 (es) 2009-06-01

Family

ID=39494539

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000555A PE20090552A1 (es) 2007-03-30 2008-03-27 Compuestos de pirimidina hidrazida como inhibidores de pgds

Country Status (25)

Country Link
US (1) US8258130B2 (es)
EP (1) EP2142516B1 (es)
JP (1) JP5427769B2 (es)
KR (1) KR20090125852A (es)
CN (1) CN101646656B (es)
AR (1) AR065874A1 (es)
AU (1) AU2008232771B2 (es)
BR (1) BRPI0809974A2 (es)
CA (1) CA2682629C (es)
CL (1) CL2008000911A1 (es)
DK (1) DK2142516T3 (es)
ES (1) ES2400622T3 (es)
IL (1) IL200898A (es)
MA (1) MA31326B1 (es)
MX (1) MX2009009443A (es)
MY (1) MY154895A (es)
NZ (1) NZ579892A (es)
PA (1) PA8774101A1 (es)
PE (1) PE20090552A1 (es)
PT (1) PT2142516E (es)
RU (1) RU2464262C2 (es)
SG (1) SG179437A1 (es)
TW (1) TWI430994B (es)
WO (1) WO2008121670A1 (es)
ZA (1) ZA200906082B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
MX2010012703A (es) 2008-05-21 2010-12-21 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
PE20110843A1 (es) 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
EP2381777A4 (en) 2008-12-12 2012-08-08 Ariad Pharma Inc AZAINDOL DERIVATIVES AS KINASEHEMMER
US8703808B2 (en) 2009-06-23 2014-04-22 Centre National De La Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
EP2266562A1 (en) * 2009-06-23 2010-12-29 Centre National de la Recherche Scientifique Use of derivatives of indoles for the treatment of cancer
CA2776242C (en) 2009-10-08 2014-09-02 Sanofi Phenyloxadiazole derivatives as pgds inhibitors
AT509045B1 (de) 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale
EP2576536B1 (en) 2010-06-01 2016-09-14 The University of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
CA2832504C (en) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
JP6063953B2 (ja) 2011-11-29 2017-01-18 シンジェンタ パーティシペーションズ アーゲー 殺虫性トリアジノン誘導体
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
PL3033336T3 (pl) 2013-08-14 2018-11-30 Kalvista Pharmaceuticals Limited Inhibitory kalikreiny w plaźmie
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
EP3165093A1 (en) 2015-11-05 2017-05-10 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
UY37028A (es) 2015-12-17 2017-07-31 Astex Therapeutics Ltd Compuestos inhibidores de prostaglandina d sintasa ematopoyética (h-pgds
UA123735C2 (uk) 2016-05-31 2021-05-26 Калвіста Фармасьютікалз Лімітед Похідні піразолу як інгібітори калікреїну
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
CA3066979A1 (en) 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
MD3716952T2 (ro) 2017-11-29 2022-06-30 Kalvista Pharmaceuticals Ltd Forme de dozare cuprizând un inhibitor de kalikreină al plasmatică
JP2021506811A (ja) 2017-12-13 2021-02-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈ−ｐｇｄｓの阻害剤として作用する縮合ピリジン
JP2022506850A (ja) 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4169575A4 (en) * 2020-06-19 2023-10-25 Sato Pharmaceutical Co., Ltd. CONDENSED RING CONNECTIONS FOR INHIBITING H-PGDS
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
WO2023113023A1 (ja) * 2021-12-17 2023-06-22 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害するアザインドール誘導体
CN116514769B (zh) * 2022-01-21 2024-02-27 中国药科大学 4-羟基嘧啶-5-甲酰腙衍生物、制备方法、药物组合物和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143173A (ja) * 1984-08-06 1986-03-01 Mitsui Petrochem Ind Ltd 新規ピリミジン誘導体およびその製法
JPS61140568A (ja) * 1984-12-14 1986-06-27 Mitsui Petrochem Ind Ltd キナゾリン誘導体及びそれを有効成分とする血圧降下剤
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
RU2343148C2 (ru) * 2002-02-01 2009-01-10 Райджел Фармасьютикалз, Инк Соединения 2,4-пиримидиндиаминов и их применение
KR20050035885A (ko) 2002-08-16 2005-04-19 아벤티스 파마슈티칼스 인크. 마이크로솜성 프로스타글란딘 ｅ 신타제 또는 조혈성 프로스타글란딘 ｄ 신타제의 활성을 감소시키는 능력에 대해 화합물 또는 제제를 검정하는 방법
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
JP2007051121A (ja) * 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
CA2673375A1 (en) * 2006-12-22 2008-07-03 Novartis Ag 1-aminomethyl-l-phenyl-cyclohexane derivatives as ddp-iv inhibitors
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
CN101668732A (zh) * 2007-04-02 2010-03-10 同一世界健康研究院 Cftr抑制剂化合物及其用途

Also Published As

Publication number Publication date
KR20090125852A (ko) 2009-12-07
AU2008232771A1 (en) 2008-10-09
TWI430994B (zh) 2014-03-21
US8258130B2 (en) 2012-09-04
DK2142516T3 (da) 2013-04-15
RU2464262C2 (ru) 2012-10-20
IL200898A0 (en) 2010-05-17
CA2682629A1 (en) 2008-10-09
RU2009140149A (ru) 2011-05-10
JP5427769B2 (ja) 2014-02-26
PT2142516E (pt) 2013-03-07
EP2142516A1 (en) 2010-01-13
CN101646656B (zh) 2013-08-14
JP2010523494A (ja) 2010-07-15
NZ579892A (en) 2012-03-30
BRPI0809974A2 (pt) 2014-10-07
MA31326B1 (fr) 2010-04-01
MX2009009443A (es) 2009-09-14
ZA200906082B (en) 2010-06-30
ES2400622T3 (es) 2013-04-11
CA2682629C (en) 2013-03-19
AR065874A1 (es) 2009-07-08
MY154895A (en) 2015-08-14
IL200898A (en) 2013-12-31
AU2008232771B2 (en) 2012-12-20
CL2008000911A1 (es) 2008-10-03
WO2008121670A1 (en) 2008-10-09
TW200906802A (en) 2009-02-16
SG179437A1 (en) 2012-04-27
CN101646656A (zh) 2010-02-10
US20100048568A1 (en) 2010-02-25
EP2142516B1 (en) 2012-12-26
PA8774101A1 (es) 2008-11-19

Similar Documents

Publication Publication Date Title
PE20090552A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
UA108240C2 (uk) Похідні гексафторізопропілкарбамату, їх одержання і їх терапевтичне застосування
NO20083669L (no) 4-aryl-2amino-pyrimidiner eller 4-aryl-2-aminoalkylpyrimidiner som jak-2-modulatorer og fremgangsmater for anvendelse derav
ECSP13013038A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CR20120053A (es) Compuestos y metodos inhibidores de jak de pirazolopirimidina
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
PE20110368A1 (es) Moduladores de mif
EA201201663A1 (ru) Производные 2-(ариламино)-3н-имидазо[4,5-b]пиридин-6-карбоксамида и их применение в качестве ингибиторов mpges-1
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
EA201291073A1 (ru) Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
NI201000157A (es) Inhibidores desacetilasas b a base de hidroxamato.
CO6160330A2 (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3
DK1943232T3 (da) Kvadratsyrederivater som inhibitorer af histondeacetylase
UY32004A (es) Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica
ECSP12011788A (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
BRPI0511433A (pt) derivados de quinolina substituìda como inibidores de cinesina mitótica
UY32246A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica
AR082230A1 (es) Derivados de triazolo- y pirazoloquinazolina como inhibidor de la enzima pde10a
PE20091079A1 (es) Compuestos heterociclicos como moduladores npy y2

Legal Events

Date Code Title Description
FC Refusal